Cargando…
Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705240/ https://www.ncbi.nlm.nih.gov/pubmed/35840724 http://dx.doi.org/10.1038/s41391-022-00578-7 |
| _version_ | 1784840235233837056 |
|---|---|
| author | Tagawa, Scott T. Ramaswamy, Krishnan Huang, Ahong Mardekian, Jack Schultz, Neil M. Wang, Li Sandin, Rickard Lechpammer, Stanislav George, Daniel J. |
| author_facet | Tagawa, Scott T. Ramaswamy, Krishnan Huang, Ahong Mardekian, Jack Schultz, Neil M. Wang, Li Sandin, Rickard Lechpammer, Stanislav George, Daniel J. |
| author_sort | Tagawa, Scott T. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9705240 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-97052402022-11-30 Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate Tagawa, Scott T. Ramaswamy, Krishnan Huang, Ahong Mardekian, Jack Schultz, Neil M. Wang, Li Sandin, Rickard Lechpammer, Stanislav George, Daniel J. Prostate Cancer Prostatic Dis Correction Nature Publishing Group UK 2022-07-15 2022 /pmc/articles/PMC9705240/ /pubmed/35840724 http://dx.doi.org/10.1038/s41391-022-00578-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Tagawa, Scott T. Ramaswamy, Krishnan Huang, Ahong Mardekian, Jack Schultz, Neil M. Wang, Li Sandin, Rickard Lechpammer, Stanislav George, Daniel J. Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate |
| title | Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate |
| title_full | Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate |
| title_fullStr | Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate |
| title_full_unstemmed | Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate |
| title_short | Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate |
| title_sort | correction: survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705240/ https://www.ncbi.nlm.nih.gov/pubmed/35840724 http://dx.doi.org/10.1038/s41391-022-00578-7 |
| work_keys_str_mv | AT tagawascottt correctionsurvivaloutcomesinpatientswithchemotherapynaivemetastaticcastrationresistantprostatecancertreatedwithenzalutamideorabirateroneacetate AT ramaswamykrishnan correctionsurvivaloutcomesinpatientswithchemotherapynaivemetastaticcastrationresistantprostatecancertreatedwithenzalutamideorabirateroneacetate AT huangahong correctionsurvivaloutcomesinpatientswithchemotherapynaivemetastaticcastrationresistantprostatecancertreatedwithenzalutamideorabirateroneacetate AT mardekianjack correctionsurvivaloutcomesinpatientswithchemotherapynaivemetastaticcastrationresistantprostatecancertreatedwithenzalutamideorabirateroneacetate AT schultzneilm correctionsurvivaloutcomesinpatientswithchemotherapynaivemetastaticcastrationresistantprostatecancertreatedwithenzalutamideorabirateroneacetate AT wangli correctionsurvivaloutcomesinpatientswithchemotherapynaivemetastaticcastrationresistantprostatecancertreatedwithenzalutamideorabirateroneacetate AT sandinrickard correctionsurvivaloutcomesinpatientswithchemotherapynaivemetastaticcastrationresistantprostatecancertreatedwithenzalutamideorabirateroneacetate AT lechpammerstanislav correctionsurvivaloutcomesinpatientswithchemotherapynaivemetastaticcastrationresistantprostatecancertreatedwithenzalutamideorabirateroneacetate AT georgedanielj correctionsurvivaloutcomesinpatientswithchemotherapynaivemetastaticcastrationresistantprostatecancertreatedwithenzalutamideorabirateroneacetate |